Archives
-
1-methyl Adenosine: Practical Assay Workflows
2026-08-16
Use 1-methyl Adenosine as both a mechanistic perturbagen and a reference analyte for RNA modification research, cancer metabolism studies, and biomarker discovery. A workflow built around careful solubility control, matched controls, and isotope-diluted UHPLC–MS/MS helps separate biological effects from matrix and isomer-resolution artifacts.
-
Deferasirox, Lysosomal Iron, and Translational Strategy
2026-08-15
Deferasirox is more than an oral iron chelator for systemic iron overload: it is a controllable probe of iron availability, mitochondrial ROS, and myeloid-cell programs. By connecting its pharmacology with the 2025 TCF25 study on glucose starvation, lysosomal acidification, ferritinophagy, and lysosome-dependent cell death, this article outlines a disciplined path from mechanistic hypothesis to translational validation.
-
Ibotenic Acid for Circuit Neuroscience Models
2026-08-14
Ibotenic acid combines NMDA and metabotropic glutamate receptor activity with practical water-based handling for controlled neural perturbation studies. This guide connects excitotoxic lesion workflows with circuit-level pain assays while emphasizing fresh preparation, bilateral behavioral analysis, and careful interpretation of nonselective neuronal injury.
-
Cryptosporidium AdhE Inhibition by Imidazoles
2026-08-14
Chen et al. characterized the bacterial-type bifunctional aldehyde/alcohol dehydrogenase CpAdhE as a potential metabolic target in Cryptosporidium parvum and screened 3,892 compounds for enzyme inhibition. Antifungal imidazoles emerged as low-micromolar CpAdhE inhibitors and also suppressed parasite growth in vitro, providing a target-to-phenotype rationale for further anti-cryptosporidial research.
-
Ceramides Drive RGNNV Infection Through Autophagy
2026-08-13
The reference study combines global lipidomics, pathway perturbation, protein localization, and rescue experiments to show that ceramide accumulation supports red-spotted grouper nervous necrosis virus replication. Its findings identify ceramide flux and autophagy as mechanistically connected, while also defining important limits for translating the work into other experimental systems.
-
Captopril: An ACE–Bradykinin Research Probe
2026-08-13
Captopril is more than a benchmark ACE inhibitor for hypertension research: it can help interrogate linked angiotensin and bradykinin biology. This article explains how the guinea pig ileum peristalsis study informs assay design, controls, and interpretation across cardiovascular, gastrointestinal, and cancer models.
-
OTUD3, SLC7A11, and Sunitinib Resistance
2026-08-12
The reference study identifies OTUD3 as a deubiquitinase that stabilizes SLC7A11, strengthens the cystine–glutathione defense system, and suppresses sunitinib-induced ferroptosis in clear cell renal cell carcinoma. Its findings provide a mechanistic explanation for drug resistance and suggest that disrupting OTUD3-dependent protein stability may restore ferroptotic sensitivity.
-
Curcumin, Wnt/β-Catenin, and Stem Cells in Colitis
2026-08-12
The reference study identifies intestinal stem cell differentiation as a mechanistic link between curcumin treatment and epithelial repair in DSS-induced ulcerative colitis. Its pathway-focused design suggests that suppressing aberrant Wnt/β-catenin signaling, rather than reducing inflammation alone, may help restore functional intestinal lineages.
-
NSC-23766 and the Rac1–GLUT4 Axis
2026-08-11
Explore how NSC-23766 can function as a mechanistic Rac GTPase inhibitor for testing the lactate–GPR81–FARP1–Rac1–GLUT4 pathway. This article translates recent metabolic findings into rigorous assay-design decisions while clarifying selectivity, controls, and interpretation limits.
-
Sulfaphenazole: From CYP2C9 Probe to Translational Lever
2026-08-11
Sulfaphenazole connects selective CYP2C9 inhibition, antibacterial pharmacology, vascular biology, and injury repair. This thought-leadership guide shows how translational researchers can use the compound as both a mechanistic probe and a strategic benchmark while separating promising biology from preclinical limitations.
-
PD98059 in Vascular Lipid Signaling Research
2026-08-10
PD98059 is a MEK inhibitor that can convert MAPK/ERK activation into a testable causal mechanism. This article examines its use in nanoplastic-induced vascular lipid dysregulation and provides assay-centered guidance beyond conventional oncology applications.
-
Mitoxantrone HCl: A Mechanism-First Assay Guide
2026-08-09
Mitoxantrone HCl is a DNA topoisomerase II inhibitor with applications that extend beyond canonical DNA damage assays. This guide develops a mechanism-first framework linking Topo-II activity, apoptosis, immune modulation, and the newly described ERα allosteric mechanism to better experimental design.
-
Bestatin as a Chemical Genetics Tool for Jasmonate Signaling
2026-08-08
The reference study shows that Bestatin, also known as Ubenimex, can activate jasmonate-responsive processes in Arabidopsis and tomato, despite its established activity against selected aminopeptidases. By combining gene-expression analysis, genetic testing, transcriptomics, and mutant screening, the authors establish Bestatin as a chemical genetics probe for discovering components of jasmonate signaling.
-
SGC-CBP30 for CREBBP/EP300 Bromodomain Studies
2026-08-07
SGC-CBP30 is a selective CREBBP/EP300 bromodomain inhibitor for testing how transcriptional coactivator function shapes enhancer activity, chromatin state, and gene expression. This workflow connects biochemical potency with practical assays for super-enhancer biology, TGF-β/SMAD3 signaling, and lung adenocarcinoma research.
-
Novobiocin (SKU BA1116): Reliable Solutions for Cell Assays
2026-08-07
This article delivers a scenario-driven, evidence-based guide to maximizing reliability and reproducibility in cell viability, proliferation, and cytotoxicity assays using Novobiocin (SKU BA1116). Drawing on validated protocols, quantitative data, and peer-reviewed literature, it addresses real-world lab challenges and demonstrates why Novobiocin is a trusted aminocoumarin antibiotic for advanced biomedical research.